Melane Sampson, Author at BioTuesdays

Executive Moves

Sigyn Therapeutics names leading nephrologist Dr. H. David Humes to SAB

Sigyn Therapeutics (OTC:SIGY) appointed internationally recognized nephrologist, H. David Humes, M.D., to its scientific advisory board. Dr. Humes recently played an instrumental role in the oversight of preclinical...

March 15, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Executive Moves

Graphite Bio names biotech analyst Alethia Young as CFO

Alethia Young Graphite Bio (NASDAQ:GRPH) appointed Alethia Young as CFO, effective April 1, to oversee the company’s finance, investor relations and corporate communications functions, and to play a key role in...

March 4, 2022

Executive Moves

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

Sigyn Therapeutics (OTC:SIGY) appointed Jeremy Ferrell as CFO, effective March 9, 2022, with overall responsibility for operational finance, budgeting, and financial reporting, as well as helping manage Sigyn’s...

March 2, 2022

Developments

FDA accepts LENSAR 510(k) submission for ALLY

The FDA accepted a 510(k) submission from LENSAR (NASDAQ:LNSR) for its next-generation ALLY Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY and is the...

March 1, 2022

Markets

Cantor starts Hepion Pharma at OW; PT $3.50

Cantor Fitzgerald launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with an “overweight” rating and $3.50 price target. The stock closed at $1.03 on Feb. 25. Hepion’s lead asset, Rencofilstat (CRV431)...

February 28, 2022

Developments

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics (OTC:SIGY) reported successful completion of an in vivo study that demonstrated Sigyn Therapy, its novel blood purification technology, to be safe and well tolerated. Data resulting from...

February 23, 2022

Executive Moves

Pipeline Therapeutics appoints Eef Schimmelpennink to board

Closely held Pipeline Therapeutics named Evert (Eef) Schimmelpennink to its board. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development...

February 22, 2022

Developments

180 Life Sciences forms scientific advisory board

180 Life Sciences (NASDAQ:ATNF) formed a scientific advisory board (SAB) whose initial composition will include Prof. Raphael Mechoulam of Hebrew University, Israel; Dr. Kevin Tracey, of Hofstra/Northwell; Prof. Irene...

February 17, 2022

Author - Melane Sampson

Sigyn Therapeutics names leading nephrologist Dr. H. David Humes to SAB

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Graphite Bio names biotech analyst Alethia Young as CFO

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

FDA accepts LENSAR 510(k) submission for ALLY

Cantor starts Hepion Pharma at OW; PT $3.50

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Pipeline Therapeutics appoints Eef Schimmelpennink to board

180 Life Sciences forms scientific advisory board

Subscribe